Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
B-cell lymphoma
Biotech
ASH: Should existing BTKs worry about Lilly's newcomer?
The three existing BTK inhibitors can't be used in patients who've failed one another. But Lilly's pirtobrutinib shows it can.
Angus Liu
Dec 12, 2022 5:30pm
FDA lifts clinical hold on Curis' phase 1/2 lymphoma trial
Aug 18, 2022 11:23am
Schrödinger gears up for clinic, eyes 'hundreds' of programs
Jul 8, 2022 10:53am
TeneoTwo, put in play by Amgen, lands $100M AstraZeneca buyout
Jul 5, 2022 7:00am
AbbVie lays down marker in fiercely competitive bispecific niche
Jun 13, 2022 8:25am
Gilead's CD47 trials freed of FDA hold—for the most part
Apr 11, 2022 5:22pm
